26 terminated. 26 Phase 1, 13 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 26 | Terminated 26 |
| Phase 2 | 13 | Terminated 13 |
Follow Small Cell Lung Cancer: new trials by email Literature Review of Small Cell Lung Cancer trials Research Report on Small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications BBI-355, Erlotinib, Futibatinib - Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma | Phase 1 | Terminated | Boundless Bio, Inc. | 85 | 2023-03-24 | 2026-08-19 |
| A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer Durvalumab, Cisplatin, Carboplatin - Non-Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 1 | Terminated | AstraZeneca | 18 | 2021-06-28 | 2025-04-17 |
| Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer XmAb18087, XmAb18087 ± Pembrolizumab - Merkel Cell Carcinoma, Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Xencor, Inc. | 4 | 2021-05-10 | 2023-04-20 |
| Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors Surufatinib and Tislelizumab _ Part 1, Surufatinib and Tislelizumab _ Part 2 - Metastatic Solid Tumor, Colorectal Cancer | Phase 1 / Phase 2 | Terminated | Hutchmed | 87 | 2021-03-05 | 2025-05-08 |
| A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC). Venetoclax, Atezolizumab, Carboplatin - Small Cell Lung Cancer | Phase 1 | Terminated | Hoffmann-La Roche | 2 | 2020-09-22 | 2021-11-08 |
| Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer APG-1252, Paclitaxel - Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Ascentage Pharma Group Inc. | 28 | 2020-08-20 | 2022-07-12 |
| Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies CTX-471, Pembrolizumab (KEYTRUDA®) - Locally Advanced Solid Tumor, Metastatic Cancer | Phase 1 | Terminated | Compass Therapeutics | 100 | 2019-05-17 | 2026-10-09 |
| DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer DS-3201b, irinotecan - Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Memorial Sloan Kettering Cancer Center | 22 | 2019-03-15 | 2024-10-10 |
| Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED) M3814, Cisplatin, Etoposide - Small Cell Lung Cancer | Phase 1 | Terminated | EMD Serono Research & Development Institute, Inc. | 2 | 2017-05-25 | 2020-09-16 |
| A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer Ipilimumab, Nivolumab, Rovalpituzumab tesirine - Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | AbbVie | 42 | 2017-03-30 | 2020-07-17 |
| A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer Rovalpituzumab Tesirine, Cisplatin, Etoposide - Small Cell Lung Cancer | Phase 1 | Terminated | AbbVie | 28 | 2016-10-01 | 2020-03-12 |
| Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer EP0057, olaparib, CT scan - Urothelial Carcinoma, Urothelial Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 45 | 2016-05-09 | 2026-08-13 |
| LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies LCL161, Topotecan, Pegylated GCSF (PEG-GCSF) - Small Cell Lung Cancer, Ovarian Cancer | Phase 1 | Terminated | SCRI Development Innovations, LLC | 34 | 2016-03-23 | 2023-12-05 |
| SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma SC-002 - Small Cell Lung Cancer | Phase 1 | Terminated | Stemcentrx | 35 | 2015-06-01 | 2018-10-05 |
| Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors Alisertib, Paclitaxel - Advanced Solid Tumors, Ovarian Cancer | Phase 1 | Terminated | Millennium Pharmaceuticals, Inc. | 9 | 2015-03-19 | 2019-06-26 |
| Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) Pembrolizumab, Gemcitabine, Docetaxel - Advanced Cancer, Breast Cancer | Phase 1 / Phase 2 | Terminated | Western Regional Medical Center | 81 | 2014-12-01 | 2018-07-02 |
| A Phase I/II Study of Ganetespib in Combination With Doxorubicin Ganetespib, Doxorubicin - Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Georgetown University | 11 | 2014-10-01 | 2018-04-23 |
| Chloroquine as an Anti-autophagic Radiosensitizing Drug in Stage I-III Small Cell Lung Cancer Chloroquine - Small Cell Lung Cancer | Phase 1 | Terminated | Maastricht Radiation Oncology | 5 | 2014-05-01 | 2017-07-18 |
| Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients Chloroquine, A-CQ 100 - Small Cell Lung Cancer | Phase 1 | Terminated | Maastricht Radiation Oncology | 5 | 2013-09-01 | 2019-02-15 |
| A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer IMGN901, Carboplatin and Etoposide - Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | ImmunoGen, Inc. | 181 | 2010-11-01 | 2018-01-18 |
Showing 20 of 26. Sign in to see all of them.
Small Cell Lung Carcinoma (26) · Lung Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (3) · Neoplasm Metastasis (2) · Neoplasms (2) · Ovarian Neoplasms (2) · Sarcoma (2) · Breast Neoplasms (1) · Carcinoid Tumor (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Small Cell (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Head and Neck Neoplasms (1) · Histiocytoma, Malignant Fibrous (1)
Bronchial Neoplasms (26) · Carcinoma, Bronchogenic (26) · Lung Diseases (26) · Neoplasms by Site (26) · Respiratory Tract Diseases (26) · Respiratory Tract Neoplasms (26) · Thoracic Neoplasms (26) · Neoplasms (24) · Lung Neoplasms (21) · Neoplasms by Histologic Type (8) · Neoplasms, Glandular and Epithelial (7) · Carcinoma (6) · Neoplasms, Germ Cell and Embryonal (4) · Neoplasms, Nerve Tissue (4) · Neuroectodermal Tumors (4)
Etoposide (8) · Carboplatin (6) · Cisplatin (5) · Albumin-Bound Paclitaxel (2) · Chloroquine (2) · Irinotecan (2) · Paclitaxel (2) · Radiation (2) · Topotecan (2) · Vorinostat (2) · pembrolizumab (2) · rovalpituzumab tesirine (2) · 130-nm albumin-bound paclitaxel (1) · Biopsy (1) · Caves (1)
AbbVie (2) · Maastricht Radiation Oncology (2) · Ahmad Tarhini (1) · Armando Santoro, MD (1) · Ascentage Pharma Group Inc. (1) · AstraZeneca (1) · Boundless Bio, Inc. (1) · Compass Therapeutics (1) · EMD Serono Research & Development Institute, Inc. (1) · Eli Lilly and Company (1) · Georgetown University (1) · Hoffmann-La Roche (1) · Hutchmed (1) · ImmunoGen, Inc. (1) · M.D. Anderson Cancer Center (1)
United States (20) · Spain (5) · Italy (3) · Netherlands (3) · Belgium (2) · Canada (2) · Denmark (2) · Germany (2) · South Korea (2) · United Kingdom (2) · Australia (1) · Bulgaria (1) · Czechia (1) · France (1) · Hungary (1)
Ahmad A Tarhini, MD (1) · Anish Thomas, M.D. (1) · Armando Santoro, MD (1) · Ashish Sangal, MD (1) · Benjamin Thompson, MD, PhD (1) · Chandra P Belani, MD (1) · Charles Rudin, MD, PhD (1) · Daniel Gomez, MD (1) · Giuseppe Giaccone, MD PhD (1) · Julia Lawrence, D.O. (1)
PMID 29119276, PMID 29594044, PMID 32438272, PMID 32897402, PMID 37129455, PMID 38172595, PMID 42820295
2008 (1), 2016 (1), 2019 (1)